An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Seres Therapeutics (NASDAQ: MCRB) announced that President and CEO Eric Shaff will participate in a panel discussion at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 9:10 a.m. ET. An audio webcast will be available on the company’s website under the 'Investors and News' section, with a replay accessible for 21 days after the event.
Seres is a leader in microbiome therapeutics, notably advancing the SER-109 program, aimed at preventing C. difficile infection recurrences, with FDA breakthrough designations. The company also evaluates SER-155 for patients undergoing stem cell transplants.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 9:10 a.m. ET.
An audio webcast of the panel discussion will be available under the “Investors and News” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.
About Seres Therapeutics Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced to prevent further recurrences of C. difficile infection and has potential to become a first-in-class oral FDA-approved microbiome therapeutic. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.
When is the Cowen 43rd Annual Health Care Conference featuring MCRB?
The Cowen 43rd Annual Health Care Conference featuring MCRB will take place on March 6, 2023, at 9:10 a.m. ET.
Who from Seres Therapeutics will speak at the conference?
Eric Shaff, President and CEO of Seres Therapeutics, will participate in the panel discussion.
Where can I listen to the MCRB conference panel discussion?
An audio webcast of the panel discussion will be available on the Seres Therapeutics website under the 'Investors and News' section.
How long will the replay of the MCRB conference be available?
The replay of the MCRB conference discussion will be available for 21 days after the event.
What is the SER-109 program related to MCRB?
The SER-109 program is designed to prevent recurrences of C. difficile infection and has received Breakthrough Therapy and Orphan Drug designations from the FDA.
